Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by AtonRa Partners

AtonRa Partners lessened its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 12.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 21,102 shares of the company’s stock after selling 3,125 shares during the period. AtonRa Partners’ holdings in Nurix Therapeutics were worth $218,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new position in Nurix Therapeutics during the third quarter worth approximately $162,000. Raymond James & Associates lifted its stake in Nurix Therapeutics by 6.0% in the 3rd quarter. Raymond James & Associates now owns 97,988 shares of the company’s stock valued at $770,000 after buying an additional 5,547 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Nurix Therapeutics by 2.9% during the third quarter. Bank of New York Mellon Corp now owns 170,286 shares of the company’s stock valued at $1,338,000 after acquiring an additional 4,816 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of Nurix Therapeutics by 14.8% during the third quarter. Principal Financial Group Inc. now owns 15,531 shares of the company’s stock valued at $122,000 after buying an additional 2,002 shares during the period. Finally, Los Angeles Capital Management LLC lifted its stake in shares of Nurix Therapeutics by 15.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 125,839 shares of the company’s stock worth $989,000 after purchasing an additional 16,989 shares during the period.

Insider Activity

In other news, CFO Houte Hans Van sold 6,812 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $10.02, for a total transaction of $68,256.24. Following the completion of the sale, the chief financial officer now owns 68,333 shares of the company’s stock, valued at $684,696.66. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 7.20% of the company’s stock.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX traded down $0.21 during midday trading on Tuesday, reaching $12.26. The company had a trading volume of 116,871 shares, compared to its average volume of 929,614. The company has a fifty day simple moving average of $13.66 and a two-hundred day simple moving average of $9.79. The firm has a market cap of $602.59 million, a price-to-earnings ratio of -4.60 and a beta of 2.06. Nurix Therapeutics, Inc. has a 1-year low of $4.22 and a 1-year high of $18.12.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Thursday, February 15th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.26). The business had revenue of $15.16 million during the quarter, compared to the consensus estimate of $30.66 million. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. Analysts expect that Nurix Therapeutics, Inc. will post -3.15 EPS for the current year.

Wall Street Analyst Weigh In

NRIX has been the subject of several research reports. HC Wainwright lowered their price objective on shares of Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, February 20th. Needham & Company LLC reissued a “buy” rating and set a $31.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, April 9th. Morgan Stanley raised their price target on shares of Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Wells Fargo & Company decreased their price objective on shares of Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Friday, February 16th. Finally, Robert W. Baird raised their target price on Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a report on Thursday, April 11th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.33.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.